Company news
Oragenics Inc. (AMEX:OGEN) news
Oragenics Inc. news releases on 6ix. Latest, May 19, 2026: Oragenics : Investor Presentation - May 2026
Press releases & updates
Oragenics : Investor Presentation - May 2026
May 19, 2026
ORAGENICS PROVIDES INVESTOR UPDATE
May 18, 2026
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7, 2026
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
May 5, 2026
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
April 20, 2026
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
April 13, 2026
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
March 25, 2026
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
March 17, 2026
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
March 12, 2026
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
March 11, 2026
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
March 10, 2026
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
February 9, 2026
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
February 3, 2026
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
February 2, 2026
Oragenics : Investor Presentation - January 2026
January 26, 2026
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
January 14, 2026
Oragenics Q3 2025 Shareholder Update
November 12, 2025
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
October 21, 2025
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
October 7, 2025
Oragenics Q2 2025 Shareholder Update
August 11, 2025
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
July 31, 2025
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
July 16, 2025
Oragenics Completes Approximately $16.5 Million Offering
July 2, 2025
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
July 1, 2025
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
June 10, 2025
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
May 28, 2025
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
May 13, 2025
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
May 12, 2025
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
April 23, 2025